156 related articles for article (PubMed ID: 28513990)
21. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T
J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836
[TBL] [Abstract][Full Text] [Related]
22. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B; Lux MP; Goecke TO; Beckmann MW
Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
[TBL] [Abstract][Full Text] [Related]
23. Effect of germ-line genetic variation on breast cancer survival in a population-based study.
Goode EL; Dunning AM; Kuschel B; Healey CS; Day NE; Ponder BA; Easton DF; Pharoah PP
Cancer Res; 2002 Jun; 62(11):3052-7. PubMed ID: 12036913
[TBL] [Abstract][Full Text] [Related]
24. BRCA1 and BRCA2 gene mutation analysis: visit to the Breast Cancer Information Core (BIC).
Shen D; Vadgama JV
Oncol Res; 1999; 11(2):63-9. PubMed ID: 10489161
[TBL] [Abstract][Full Text] [Related]
25. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
[TBL] [Abstract][Full Text] [Related]
26. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
27. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
28. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
[TBL] [Abstract][Full Text] [Related]
29. Reproductive factors as risk modifiers of breast cancer in
Park B; Hopper JL; Win AK; Dowty JG; Sung HK; Ahn C; Kim SW; Lee MH; Lee J; Lee JW; Kang E; Yu JH; Kim KS; Moon BI; Han W; Noh DY; Park SK;
Oncotarget; 2017 Nov; 8(60):102110-102118. PubMed ID: 29254229
[TBL] [Abstract][Full Text] [Related]
30. Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
Kolben T; Hary T; Holdt LM; Schwarz TM; Goess C; Wuerstlein R; Gallwas J; Toth B; Weissenbacher T; Jeschke U; Harbeck N; Ditsch N
Anticancer Res; 2016 Jun; 36(6):3185-90. PubMed ID: 27272846
[TBL] [Abstract][Full Text] [Related]
31. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.
Huzarski T; Byrski T; Gronwald J; Górski B; Domagala P; Cybulski C; Oszurek O; Szwiec M; Gugala K; Stawicka M; Morawiec Z; Mierzwa T; Janiszewska H; Kilar E; Marczyk E; Kozak-Klonowska B; Siolek M; Surdyka D; Wisniowski R; Posmyk M; Sun P; Lubinski J; Narod SA
J Clin Oncol; 2013 Sep; 31(26):3191-6. PubMed ID: 23940229
[TBL] [Abstract][Full Text] [Related]
32. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
[TBL] [Abstract][Full Text] [Related]
33. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
[TBL] [Abstract][Full Text] [Related]
34. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
[TBL] [Abstract][Full Text] [Related]
35. FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
Kiiski JI; Fagerholm R; Tervasmäki A; Pelttari LM; Khan S; Jamshidi M; Mantere T; Pylkäs K; Bartek J; Bartkova J; Mannermaa A; Tengström M; Kosma VM; Winqvist R; Kallioniemi A; Aittomäki K; Blomqvist C; Nevanlinna H
Int J Cancer; 2016 Dec; 139(12):2760-2770. PubMed ID: 27542569
[TBL] [Abstract][Full Text] [Related]
36. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations.
Brunet J; Gutiérrez-Enríquez S; Torres A; Bérez V; Sanjosé S; Galceran J; Izquierdo A; Menéndez JA; Gumà J; Borràs J
Clin Genet; 2008 May; 73(5):465-73. PubMed ID: 18384426
[TBL] [Abstract][Full Text] [Related]
37. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.
De Felice F; Marchetti C; Musella A; Palaia I; Perniola G; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Ann Surg Oncol; 2015 Sep; 22(9):2876-80. PubMed ID: 25808098
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
39. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Palanca Suela S; Esteban Cardeñosa E; Barragán González E; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Montalar Salcedo J; Castel Sánchez V; Bolufer Gilabert P;
Breast Cancer Res Treat; 2010 Jan; 119(1):87-93. PubMed ID: 19214744
[TBL] [Abstract][Full Text] [Related]
40. Four novel MSH2 and MLH1 frameshift mutations and occurrence of a breast cancer phenocopy in hereditary nonpolyposis colorectal cancer.
Caluseriu O; Cordisco EL; Viel A; Majore S; Nascimbeni R; Pucciarelli S; Genuardi M
Hum Mutat; 2001 Jun; 17(6):521. PubMed ID: 11385712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
